Literature DB >> 17689532

A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder.

Linda L Werling1, Ashleigh Keller, Julie G Frank, Samer J Nuwayhid.   

Abstract

We compared the binding profiles of medications potentially useful in the treatment of involuntary emotional expression disorder at twenty-six binding sites in rat brain tissue membranes. Sites were chosen based on likelihood of being target sites for the mechanism of action of the agents in treating the disorder or their likelihood in producing side effects experienced by patients treated with psychoactive agents. We used radioligand binding assays employing the most selective labeled ligands available for sites of interest. Concentrations of labeled ligand were used at or below the K(i) value of the ligand for the target site. Compounds were initially screened at 1 muM. For compounds that competed for greater than 20-30% of specific binding at target sites of interest, full concentration curves were constructed. Dextromethorphan, amitriptyline and fluoxetine competed for binding to sigma(1) receptors and to serotonin transporters with high to moderate affinity. Of the target sites tested, these are the most likely to contribute to the therapeutic benefit of the various agents. In addition, all three drugs showed some activity at alpha(2) and 5-HT(1B/D) sites. Of the drugs tested, dextromethorphan bound to the fewest sites unlikely to be target sites. Although the mechanism of action of dextromethorphan or any drug that has been used in the treatment of involuntary emotional expression disorder is currently unknown, our data support that the affinity of the drug for sigma(1) receptors is consistent with its possible action through this receptor type in controlling symptoms of the disorder.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17689532     DOI: 10.1016/j.expneurol.2007.06.013

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  29 in total

1.  New index of pain triggered by spinal activation of voltage-dependent sodium channels.

Authors:  Ryugo Enomoto; Mina Tsukamoto; Yukinori Shimoshige; Toshiaki Aoki; Nobuya Matsuoka
Journal:  J Anesth       Date:  2013-06-13       Impact factor: 2.078

2.  Characterization of pulmonary sigma receptors by radioligand binding.

Authors:  John R Lever; Tyler P Litton; Emily A Fergason-Cantrell
Journal:  Eur J Pharmacol       Date:  2015-05-22       Impact factor: 4.432

Review 3.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

4.  Treatment Resistant Depression with Loss of Antidepressant Response: Rapid-Acting Antidepressant Action of Dextromethorphan, A Possible Treatment Bridging Molecule.

Authors:  Edward C Lauterbach
Journal:  Psychopharmacol Bull       Date:  2016-08-15

Review 5.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

6.  Slow-release delivery enhances the pharmacological properties of oral 5-hydroxytryptophan: mouse proof-of-concept.

Authors:  Jacob P R Jacobsen; Adrianna Oh; Rachel Bangle; Wendy L Roberts; Elizabeth L Royer; Nathan Modesto; Sonora A Windermere; Zixuan Yi; Rebecca Vernon; Manuel Cajina; Nikhil M Urs; Joshua C Snyder; Peter J Nicholls; Benjamin D Sachs; Marc G Caron
Journal:  Neuropsychopharmacology       Date:  2019-04-29       Impact factor: 7.853

Review 7.  Dextromethorphan/quinidine: a review of its use in adults with pseudobulbar affect.

Authors:  Lily P H Yang; Emma D Deeks
Journal:  Drugs       Date:  2015-01       Impact factor: 9.546

8.  Acute cognitive effects of high doses of dextromethorphan relative to triazolam in humans.

Authors:  Lawrence P Carter; Chad J Reissig; Matthew W Johnson; Margaret A Klinedinst; Roland R Griffiths; Miriam Z Mintzer
Journal:  Drug Alcohol Depend       Date:  2012-09-16       Impact factor: 4.492

9.  SSRI Augmentation by 5-Hydroxytryptophan Slow Release: Mouse Pharmacodynamic Proof of Concept.

Authors:  Jacob Pr Jacobsen; Meghan L Rudder; Wendy Roberts; Elizabeth L Royer; Taylor J Robinson; Adrianna Oh; Ivan Spasojevic; Benjamin D Sachs; Marc G Caron
Journal:  Neuropsychopharmacology       Date:  2016-03-02       Impact factor: 7.853

10.  Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors.

Authors:  Melanie A Paquette; Alex A Martinez; Teresa Macheda; Charles K Meshul; Steven W Johnson; S Paul Berger; Andrea Giuffrida
Journal:  Eur J Neurosci       Date:  2012-08-03       Impact factor: 3.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.